Detalhe da pesquisa
1.
Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B.
Am J Gastroenterol
; 118(7): 1214-1225, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36599136
2.
Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
Gastroenterology
; 147(1): 119-131.e3, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24657484
3.
Telaprevir for previously untreated chronic hepatitis C virus infection.
N Engl J Med
; 364(25): 2405-16, 2011 Jun 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-21696307
4.
Telaprevir for previously treated chronic HCV infection.
N Engl J Med
; 362(14): 1292-303, 2010 Apr 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-20375406
5.
Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
J Clin Gastroenterol
; 47(9): 786-93, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23442834
6.
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.
Gastroenterology
; 140(3): 840-9; quiz e12, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21129375
7.
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.
Am J Gastroenterol
; 107(9): 1388-98, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22688849
8.
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.
Hepatology
; 53(4): 1100-8, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21480316
9.
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.
Hepatology
; 54(2): 396-405, 2011 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-21520194
10.
Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C.
Gastroenterology
; 138(7): 2321-31, 2331.e1-2, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20211180
11.
Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C.
Hepatology
; 52(6): 1906-14, 2010 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21064034
12.
Outcome of sustained virological responders with histologically advanced chronic hepatitis C.
Hepatology
; 52(3): 833-44, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20564351
13.
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease.
Gastroenterology
; 136(1): 138-48, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18848939
14.
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
Gastroenterology
; 137(6): 1986-94, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19747918
15.
Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients.
Hepatology
; 49(3): 729-38, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19072828
16.
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
Hepatology
; 49(6): 1828-37, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19291787
17.
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.
Hepatology
; 50(5): 1360-9, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19676128
18.
Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial.
Hepatology
; 49(6): 1847-58, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19434718
19.
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.
Ann Intern Med
; 150(8): 528-40, 2009 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-19380853
20.
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin.
Hepatology
; 48(4): 1033-43, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18697207